
NVAX Stock Price Up 35% Now as Novavax Gets $1.6 Billion Grant for COVID-19 Vaccine Development
NVAX stock price is skyrocketing these days as Novavax is getting one step closer to the development of its coronavirus vaccine.
NVAX stock price is skyrocketing these days as Novavax is getting one step closer to the development of its coronavirus vaccine.
Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate. NVAX stock is up.
Novavax (NVAX) has jumped by 16% in the pre-market. The company has announced human trials its COVID-19 vaccine.
Novavax (NVAX) and Moderna (MRNA) stocks remain a buy amid the coronavirus economic disruption. They are 7% and 27% up in the pre-market respectively.
Novavax (NVAX) stock climbed 25% yesterday, adding to its current 2020 gains, as the company makes progress on its COVID-19 vaccine candidate. However, today NVAX is 14% down.
Novavax (NVAX) stock jumped again yesterday after it received a $4 million award to be pumped into developing a vaccine for COVID-19. However, today it is falling.
Dow Jones has lost over 1,880 points due to a row of factors including Saudi’s oil price slash as well as the coronavirus that is quickly spreading. More bleeding is expected.
As most stock markets continue bleeding out due to the coronavirus outbreak, three biotech stocks have been defying the urge as the companies are working on a vaccine or a cure for the deadly coronavirus.